Abstract:Objectives The clinical data of patients with double-positive for leucine-rich glioma-inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies is limited, particularly for children. This study aimed to investigate and summarize the clinical features and long-term prognosis of children’s LGI1 and CASPR2 antibodies related to neurological disorders. Methods We collected the clinical data and prognosis of patients with dual positive antibodies of CASPR2 and LGI1, hospitalized in the Department of Neurology, Children’s Hospital of Chongqing Medical University. Furthermore, we summarized the clinical phenotypes of this disorder in children by reviewing the published literature. Results Two patients presenting with variable neurological symptoms including pain, hypertension, profuse sweating, irritability, and dyssomnia from Children’s Hospital of Chongqing Medical University were enrolled in this study. Together with the two patients, we identified 17 children with dual CASPR2 and LGI1 antibodies, including 12 males and 5 females. At the onset, the median age was 4.1 years (range 1–16, interquartile range 2.5–13.5), with 9 children younger than 5 years and 6 adolescents. Of the 17 patients, 11 were diagnosed with Morvan syndrome, 4 with acquired neuromyotonia, 1 with Guillain-Barré syndrome, and 1 with Guillain-Barré syndrome combined with Morvan syndrome. Dysautonomia (14/17, 82.3%), pain (13/17, 76.4%), sleep disorders (13/17, 76.4%), encephalopathy (12/17, 70.5%), and weight loss (10/17, 58.8%) were the most frequently described symptoms overall. No tumors were identified. Of the 17 patients, 13 received immunotherapy comprising IVIG combination of IVMP during the acute symptomatic phase followed by oral prednisolone to maintain remission ( n = 7), the combination of IVIG, IVMP, oral prednisolone and methotrexate ( n = 1), the combination of IVIG, IVMP, and mycophenolate mofetil ( n = 1), the combination of IVIG, IVMP, oral prednisolone, and rituximab ( n = 1), IVIG only ( n = 2), IVMP only ( n = 1). Median modified Rankin Scale (mRS) scores in the acute phase were 3 (range 1–4) and improved gradually. Over the follow-up (median 8.6 months, range 1–36 months), 52.9% (9/17) of the patients recovered completely; one patient relapsed and showed immunotherapy-dependent. Conclusion LGI1 and CASPR2 double-positive antibodies associated with the neurological diseases can occur in children of all ages and involve multiple nervous systems. Morvan syndrome is the most common phenotype of this disorder. The long-term outcomes are mostly favorable upon immunotherapy.

Kelch-like Protein 11 (KLHL11) Antibodies in Children With Seizures of Undetermined Cause

Kelch-like protein 11 antibody-associated paraneoplastic neurological syndrome: A state-of-the-art review

Anti-Kelch-like protein 11 antibody encephalitis: a case report and literature review

Seizure Occurrence in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis

Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders

Peripherally-derived LGI1-reactive monoclonal antibodies cause epileptic seizures in vivo

Evaluation of GFAP, S100B, and UCHL-1 Levels in Children With Refractory Epilepsy

KCNT1-related epilepsy: An international multicenter cohort of 27 pediatric cases

Anti-LGI1 encephalitis with initiating symptom of seizures in children

Investigation of neuronal auto-antibodies in systemic lupus erythematosus patients with epilepsy

Bilateral hearing loss preceding rhomboencephalitis – a hint for Kelch-like 11 syndrome

The epilepsy phenotype of KCNK4-related neurodevelopmental disease

High frequency of cerebrospinal fluid autoantibodies in patients with seizures or epilepsies of unknown etiology

Phenotypic Spectrum of CASPR2 and LGI1 Antibodies Associated Neurological Disorders in Children

Higher incidence of acute symptomatic seizures in probable antibody-negative pediatric autoimmune encephalitis than in major antibody-positive autoimmune encephalitis

Kininogen Level in the Cerebrospinal Fluid May Be a Potential Biomarker for Predicting Epileptogenesis

High Mobility Group Protein B1 (HMGB1) and Interleukin-1β As Prognostic Biomarkers of Epilepsy in Children

Clinical analysis of leucine-rich glioma inactivated-1 protein antibody associated with limbic encephalitis onset with seizures

Clinical and genetic analysis of 23 Chinese children with epilepsy associated with KCNQ2 gene mutations

Novel variant ANKRD11 gene mutation associated with drug-resistant epilepsy in KBG syndrome phenotype

Association of High Plasma Levels of Serpin E1, IGFBP2, and CCL5 with Refractory Epilepsy in Children by Cytokine Profiling.